Table 6.

Integrated CANVAS 1 and 2: MIC ranges for selected isolates from the primary infection site (ME population)

Organism	No of isolates	Ceftaroline
		MIC range (μg/mL)	No of isolates	MIC range (μg/mL)
Gram positive pathogens				Vancomycin
Staphylococcus aureus	377	0.06 to 2	357	≤0.25 to 2
MRSA	150	0.25 to 2	121	0.5 to 2
MSSA	227	0.06 to 0.5	236	≤0.25 to 2
Streptococcus pyogenes	55	≤0.004 to 0.008	58	0.25 to 1
Streptococcus agalactiae	20	0.008 to 0.015	18	0.25 to 0.5
Enterococcus faecalis	25	0.25 to 16	24	0.5 to 2
Gram negative pathogens				Aztreonam
Pseudomonas aeruginosa	16	4 to >16	18	1 to >32
Escherichia coli	21	0.015 to >16	21	≤0.03 to 0.5
Klebsiella pneumoniae	18	0.03 to >16	14	≤0.03 to >32
Proteus mirabilis	15	≤0.008 to >16	21	≤0.03 to 16

Note: Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51(6):641–650, by permission of Oxford University Press.66

Abbreviations: CANVAS, ceftaroline versus v ancomycin in skin and skin structure infections; MIC, minimum inhibitory concentration; ME, microbiologically evaluable; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus.